Literature DB >> 10973446

Prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae immunoglobulin G and A antibodies in a healthy Finnish population as analyzed by quantitative enzyme immunoassays.

T Tuuminen1, S Varjo, H Ingman, T Weber, J Oksi, M Viljanen.   

Abstract

Chlamydia pneumoniae and Mycoplasma pneumoniae immunoglobulin G (IgG) and IgA antibody seroprevalence rates and antibody levels related to age and gender were studied. The samples (n = 742) were collected during a nonepidemic period and analyzed by quantitative enzyme immunoassays (EIAs). Seroprevalence to C. pneumoniae was found to increase sharply in young children, and in the 15- to 19-year-old group it reached levels as high as 70 and 60% for IgG and IgA, respectively. After adolescence, seroprevalence showed a transient decrease and then continued to increase, although less dramatically than in early childhood. In the elderly the seroprevalence of IgG antibodies reached 75 and 100% in women and men, respectively. The corresponding rates of IgA antibodies were 73 and 100%. When a randomly selected subgroup of samples (n = 66) was analyzed in parallel by a microimmunofluorescence test and an EIA for C. pneumoniae IgA antibodies, similar seroprevalence rates were obtained (36 versus 35%). Seroprevalence to M. pneumoniae was already found to increase very sharply in 2- to 4-year-old children, reaching 16% for IgG and 8% for IgA. Seroprevalence to M. pneumoniae also continued to increase in adolescence, but in contrast to that to C. pneumoniae, the increase leveled off at about 40 to 50% in adulthood. In subjects aged over 65 years, prevalence did not exceed 60% for IgG or 35% for IgA. The seroprevalence patterns as well as the medians and variations of levels of C. pneumoniae and M. pneumoniae IgG antibodies were similar to those of corresponding IgA antibodies. Compared to IgG antibodies, IgA antibodies do not seem to be of additional value in the diagnosis of infections caused by these pathogens when single serum specimens are studied.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10973446      PMCID: PMC95947          DOI: 10.1128/CDLI.7.5.734-738.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  11 in total

1.  Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study.

Authors:  D P Strachan; D Carrington; M A Mendall; L Ballam; J Morris; B K Butland; P M Sweetnam; P C Elwood
Journal:  BMJ       Date:  1999-04-17

2.  Pneumonia with serological evidence of acute infection with the Chlamydia-like microorganism "Z".

Authors:  D Lieberman; S Kahane; D Lieberman; M G Friedman
Journal:  Am J Respir Crit Care Med       Date:  1997-08       Impact factor: 21.405

3.  Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.

Authors:  P Saikku; M Leinonen; K Mattila; M R Ekman; M S Nieminen; P H Mäkelä; J K Huttunen; V Valtonen
Journal:  Lancet       Date:  1988-10-29       Impact factor: 79.321

4.  Detection of antibodies to Mycoplasma pneumoniae adhesion P1 in serum specimens from infected and non-infected subjects by immunoblotting.

Authors:  W Rastawicki; R Räty; M Kleemola
Journal:  Diagn Microbiol Infect Dis       Date:  1996 Nov-Dec       Impact factor: 2.803

5.  Chlamydia pneumoniae IgG antibody prevalence in south-western and eastern Finland in 1982 and 1987.

Authors:  M Karvonen; J Tuomilehto; J Pitkäniemi; A Naukkarinen; P Saikku
Journal:  Int J Epidemiol       Date:  1994-02       Impact factor: 7.196

6.  Comparison of five serologic tests for diagnosis of acute infections by Chlamydia pneumoniae.

Authors:  K Persson; J Boman
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

7.  Cardiovascular disease risk factors in young children in the STRIP baby project. Special Turku coronary Risk factor Intervention Project for children.

Authors:  O Simell; H Niinikoski; J Viikari; L Rask-Nissilä; A Tammi; T Rönnemaa
Journal:  Ann Med       Date:  1999-04       Impact factor: 4.709

8.  Molecular evidence for the existence of additional members of the order Chlamydiales.

Authors:  Jacobus M Ossewaarde; Adam Meijer
Journal:  Microbiology       Date:  1999-02       Impact factor: 2.777

Review 9.  A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

Authors:  J T Grayston; L A Campbell; C C Kuo; C H Mordhorst; P Saikku; D H Thom; S P Wang
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

Review 10.  Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients.

Authors:  H M Foy
Journal:  Clin Infect Dis       Date:  1993-08       Impact factor: 9.079

View more
  16 in total

1.  Immunological fingerprinting method for differentiation of serum samples in research-oriented biobanks.

Authors:  Katy Beaumont; Fotini Betsou
Journal:  Clin Vaccine Immunol       Date:  2010-02-17

2.  Investigation of a Chlamydia pneumoniae outbreak in a Federal correctional facility in Texas.

Authors:  Laura Conklin; Jennifer Adjemian; Jennifer Loo; Sema Mandal; Carol Davis; Sharyn Parks; Tina Parsons; Brian McDonough; Jorge Partida; Kathleen Thurman; Maureen H Diaz; Alvaro Benitez; Tracy Pondo; Cynthia G Whitney; Jonas M Winchell; Newton Kendig; Chris Van Beneden
Journal:  Clin Infect Dis       Date:  2013-05-30       Impact factor: 9.079

3.  Development and evaluation of real-time PCR-based fluorescence assays for detection of Chlamydia pneumoniae.

Authors:  Maria Lucia C Tondella; Deborah F Talkington; Brian P Holloway; Scott F Dowell; Karyn Cowley; Montse Soriano-Gabarro; Mitchell S Elkind; Barry S Fields
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

4.  Evaluation of the Virclia® automated chemiluminescent immunoassay system for diagnosing pneumonia caused by Mycoplasma pneumoniae.

Authors:  Victoria Ortiz de la Tabla; Marta Berruezo; Elena García Payá; Marta Fernández; José Alberto García; Mar Masiá; Félix Gutiérrez
Journal:  J Clin Lab Anal       Date:  2018-03-06       Impact factor: 2.352

5.  Prevalence and persistence of Chlamydia pneumoniae antibodies in healthy laboratory personnel in Finland.

Authors:  Mika Paldanius; Aini Bloigu; Marianne Alho; Maija Leinonen; Pekka Saikku
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

6.  Measurement of Chlamydia pneumoniae-specific immunoglobulin A (IgA) antibodies by the microimmunofluorescence (MIF) method: comparison of seven fluorescein-labeled anti-human IgA conjugates in an in-house MIF test using one commercial MIF and one enzyme immunoassay kit.

Authors:  Mika Paldanius; Aini Bloigu; Maija Leinonen; Pekka Saikku
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

7.  Importance of methodology in determination of Chlamydia pneumoniae seropositivity in healthy subjects and in patients with coronary atherosclerosis.

Authors:  V Y Hoymans; J M Bosmans; L Van Renterghem; R Mak; D Ursi; F Wuyts; C J Vrints; M Ieven
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

8.  Identification, expression and serological evaluation of the recombinant ATP synthase beta subunit of Mycoplasma pneumoniae.

Authors:  Hélène Nuyttens; Camille Cyncynatus; Hélène Renaudin; Sabine Pereyre; Cécile Bébéar
Journal:  BMC Microbiol       Date:  2010-08-11       Impact factor: 3.605

9.  Persistently elevated IgA antibodies to Mycoplasma pneumoniae in patients with internal carotid artery stenosis.

Authors:  Florian Daxböck; Afshin Assadian; Thomas Watkins-Riedel; Ojan Assadian
Journal:  GMS Krankenhhyg Interdiszip       Date:  2011-12-15

10.  The seroprevalence of Mycoplasma pneumoniae IgM and IgG antibodies in patients with ischemic stroke.

Authors:  Maryam Roham; Khatereh Anbari; Samira Mirhabibi; Gholamreza Goudarzi
Journal:  Iran J Microbiol       Date:  2016-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.